Cargando…
Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
BACKGROUND: Most patients with multiple myeloma (MM) will relapse after an initial response and eventually succumb to their disease. This is due to the persistence of chemotherapy-resistant tumor cells in the patients’ bone marrow (BM) and immunotherapeutic approaches could contribute to eradicating...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474344/ https://www.ncbi.nlm.nih.gov/pubmed/26088750 http://dx.doi.org/10.1186/s12967-015-0562-5 |